Piper Sandler analyst David Amsellem lowered the firm’s price target on Neurocrine to $95 from $103 and keeps a Neutral rating on the shares post the Q4 results. The company’s operating leverage for 2023 looks "tepid," the analyst tells investors in a research note. The firm remains cautious on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine sees FY23 INGREZZA net product sales $1.67B-$1.77B
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
- Neurocrine reports Q4 non-GAAP EPS $1.24, consensus $1.14
- Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023